A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes

OBJECTIVE To develop a patient-level simulation model for predicting lifetime health outcomes of patients with type 1 diabetes and as a tool for economic evaluation of type 1 diabetes treatment based on data from a large, longitudinal cohort. RESEARCH DESIGN AND METHODS Data for model development were obtained from the Swedish National Diabetes Register. We derived parametric proportional hazards models predicting the absolute risk of diabetes complications and death based on a wide range of clinical variables and history of complications. We used linear regression models to predict risk factor progression. Internal validation was performed, estimates of life expectancies for different age-sex strata were computed, and the impact of key risk factors on life expectancy was assessed. RESULTS The study population consisted of 27,841 patients with type 1 diabetes with a mean duration of follow-up of 7 years. Internal validation showed good agreement between the predicted and observed cumulative incidence of death and 10 complications. Simulated life expectancy was ∼13 years lower than that of the sex- and age-matched general population, and patients with type 1 diabetes could expect to live with one or more complications for ∼40% of their remaining life. Sensitivity analysis showed the importance of preventing renal dysfunction, hypoglycemia, and hyperglycemia as well as lowering HbA1c in reducing the risk of complications and death. CONCLUSIONS Our model was able to simulate risk factor progression and event histories that closely match the observed outcomes and to project events occurring over patients’ lifetimes. The model can serve as a tool to estimate the impact of changing clinical risk factors on health outcomes to inform economic evaluations of interventions in type 1 diabetes.

[1]  Jennifer M. Cooper,et al.  Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model , 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  G. Nordin.  Accuracy of HbA1c as Monitored by External Quality Assessment and Compared With Patient Mean Values , 2018, Journal of diabetes science and technology.

[3]  Irl B Hirsch,et al.  The Hybrid Closed-Loop System: Evolution and Practical Applications. , 2018, Diabetes technology & therapeutics.

[4]  V. Vallon,et al.  The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus , 2018, Drugs.

[5]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  J. Ludvigsson,et al.  The Swedish cause of death register , 2017, European Journal of Epidemiology.

[7]  K. Boye,et al.  The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  R. Testa,et al.  The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications , 2017, Nutrients.

[9]  Björn Eliasson,et al.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[10]  P. Cram,et al.  Understanding Preferences for Osteoporosis Information to Develop an Osteoporosis Patient Education Brochure. , 2017, The Permanente journal.

[11]  A. Klatsky,et al.  Body Mass Index and Mortality in a Very Large Cohort: Is It Really Healthier to Be Overweight? , 2017, The Permanente journal.

[12]  B. Ho,et al.  The effect of cumulative glycemic burden on the incidence of diabetic foot disease , 2016, Journal of Orthopaedic Surgery and Research.

[13]  P. Clarke,et al.  Recent trends in life expectancy for people with type 1 diabetes in Sweden , 2016, Diabetologia.

[14]  M. Willis,et al.  A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Claudio Cobelli,et al.  A Dynamic Bayesian Network model for long-term simulation of clinical complications in type 1 diabetes , 2015, J. Biomed. Informatics.

[16]  A. Briggs,et al.  Development and validation of a cost–utility model for Type 1 diabetes mellitus , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[17]  Vincenzo Lagani,et al.  Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. , 2015, Journal of diabetes and its complications.

[18]  S. Gudbjörnsdottir,et al.  Diabetes care--improvement through measurement. , 2014, Diabetes research and clinical practice.

[19]  W. Herman,et al.  Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden , 2014, Diabetes Care.

[20]  D. Nathan,et al.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview , 2013, Diabetes Care.

[21]  R. R. Holman,et al.  UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 , 2013, Diabetologia.

[22]  John Hornberger,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[23]  A. Farmer,et al.  Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes , 2013, PharmacoEconomics.

[24]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  Karl Claxton,et al.  Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[27]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[28]  J. Ludvigsson,et al.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research , 2009, European Journal of Epidemiology.

[29]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[30]  Philip M Clarke,et al.  Development of life-expectancy tables for people with type 2 diabetes. , 2009, European heart journal.

[31]  Ronald Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. , 2008, Ophthalmology.

[32]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[33]  Gretchen A. Piatt,et al.  Deficiencies of Cardiovascular Risk Prediction Models for Type 1 Diabetes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[34]  R. Klein,et al.  The 30-Year Natural History of Type 1 Diabetes Complications , 2006, Diabetes.

[35]  R. Holman,et al.  A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.

[36]  Volker Foos,et al.  The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.

[37]  Ping Zhang,et al.  Guidelines for computer modeling of diabetes and its complications , 2004 .

[38]  Björn Eliasson,et al.  The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. , 2003, Diabetes care.

[39]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[40]  G L Myers,et al.  The national glycohemoglobin standardization program: a five-year progress report. , 2001, Clinical chemistry.

[41]  A J Palmer,et al.  The Mt. Hood challenge: cross-testing two diabetes simulation models. , 2000, Diabetes research and clinical practice.

[42]  A. Palmer,et al.  The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective , 2000, Diabetologia.

[43]  M. Thun,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[44]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[45]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[46]  P. Wilson,et al.  Coronary risk prediction in adults (the Framingham Heart Study) , 1987, The American journal of cardiology.

[47]  R Kay,et al.  Goodness of fit methods for the proportional hazards regression model: a review. , 1984, Revue d'epidemiologie et de sante publique.